<?xml version="1.0" encoding="UTF-8"?>
<p id="para200">In the WHO Research and Development BluePrint meeting in Geneva on Feb 10, 2020, leading health experts from around the world recognised that sole reliance on molecular testing is not sufficient to fight this rapidly growing epidemic. The need to find more accessible testing modalities was highlighted as one of the eight 
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/blueprint/priority-diseases/key-action/Global_Research_Forum_FINAL_VERSION_for_web_14_feb_2020.pdf?ua=1" id="interrefs10" xmlns:xlink="http://www.w3.org/1999/xlink">Research and Development priorities</ext-link>, of which the top priority is to “Mobilize research on rapid point of care diagnostics for use at the community level.”
</p>
